Cargando…
Cell cycle perturbation induced by gemcitabine in human tumor cells in cell culture, xenografts and bladder cancer patients: implications for clinical trial designs combining gemcitabine with a Chk1 inhibitor
Gemcitabine irreversibly inhibits ribonucleotide reductase and induces S phase arrest but whether this occurs in tumors in mice or patients has not been established. Tumor cells in culture were incubated with gemcitabine for 6 h to approximate the administration schedule in a patient. Concentrations...
Autores principales: | Montano, Ryan, Khan, Nadeem, Hou, Huagang, Seigne, John, Ernstoff, Marc S., Lewis, Lionel D., Eastman, Alan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5620209/ https://www.ncbi.nlm.nih.gov/pubmed/28978069 http://dx.doi.org/10.18632/oncotarget.18834 |
Ejemplares similares
-
Sensitization of human cancer cells to gemcitabine by the Chk1 inhibitor MK-8776: cell cycle perturbation and impact of administration schedule in vitro and in vivo
por: Montano, Ryan, et al.
Publicado: (2013) -
Inhibition of CHK1 sensitizes Ewing sarcoma cells to the ribonucleotide reductase inhibitor gemcitabine
por: Goss, Kelli L, et al.
Publicado: (2017) -
The Mre11 Nuclease Is Critical for the Sensitivity of Cells to Chk1 Inhibition
por: Thompson, Ruth, et al.
Publicado: (2012) -
Inhibition of checkpoint kinase 2 (CHK2) enhances sensitivity of pancreatic adenocarcinoma cells to gemcitabine
por: Duong, Hong-Quan, et al.
Publicado: (2013) -
Suppression of the FA pathway combined with CHK1 inhibitor hypersensitize lung cancer cells to gemcitabine
por: Dai, Chun-Hua, et al.
Publicado: (2017)